Outcome of early short course corticosteroid therapy in severe community-acquired pneumonia: a randomised controlled trial
Open Access
- 9 February 2026
- journal article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (8) , 697-702
Abstract
Objective To evaluate the efficacy and safety of adjunctive dexamethasone in children with severe community-acquired pneumonia (CAP). Design Double-blind, randomised, placebo-controlled trial. Setting Tertiary care hospital. Patients: Children aged 2 months to 15 years diagnosed with severe CAP. Intervention Participants were randomised to receive intravenous dexamethasone or placebo for 5 days, in addition to standard antimicrobial therapy. Main outcome measures The primary outcome was treatment failure at 72 hours. Secondary outcomes included radiographic progression, respiratory failure, need for ventilation, shock, mortality, length of hospital stay, 4-week readmission and inflammatory markers. Results 132 children were enrolled (66 per group). Treatment failure at 72 hours occurred in 25.8% in the dexamethasone group vs 60.6% in the placebo group (HR 0.32; 95% CI 0.18 to 0.57; p=0.001). Radiographic worsening was significantly lower in the dexamethasone group (22.7% vs 57.6%; OR 0.22; p=0.001), as was progression to respiratory failure (10.6% vs 31.8%; OR 0.25; p=0.004). No significant differences were observed in need for ventilation, development of shock, mortality, hospital stay or readmission rates. While the reduction in erythrocyte sedimentation rate (ESR) from baseline to 72 hours was greater in the dexamethasone group, absolute ESR values at 72 hours did not differ consistently between groups, whereas no significant differences were observed in high-sensitivity C reactive protein, interleukin (IL)-6, IL-8 or IL-10. Conclusions Dexamethasone as adjunctive therapy in severe paediatric CAP significantly reduced early treatment failure and systemic inflammation without increasing adverse outcomes. These findings support its consideration in the management of severe CAP in children. Trial registration number CTRI/2021/09/036799.Keywords
Funding Information
- Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India (JIP/Res/Intramural/phs 2/2021-22)
This publication has 19 references indexed in Scilit:
- Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired PneumoniaChest, 2022
- Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysisThe Lancet Global Health, 2019
- Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory ResponseJAMA, 2015
- The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restoreTrends in Endocrinology & Metabolism, 2013
- Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in childrenPediatric Pulmonology, 2013
- Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012Intensive Care Medicine, 2013
- Adjuvant steroid therapy in community‐acquired pneumonia: A systematic review and meta‐analysisJournal of Hospital Medicine, 2012
- Efficacy of methylprednisolone in children with severe community acquired pneumoniaPediatric Pulmonology, 2012
- Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: A meta-analysis of randomized controlled trialsJournal of Critical Care, 2010
- Randomization and allocation concealment: a practical guide for researchersJournal of Critical Care, 2005